BPC-157 Legal & Patent Challenges: FDA Status, Compounding Rules, and What Patients Should Know

Print or save as PDF

See the public record for BPC-157

Is BPC-157 an FDA-approved drug?

No. No FDA-approved drug contains BPC-157, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

BPC-157 is a synthetic peptide of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1].

FDA also noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'. Those products are not FDA-approved drugs [1].

How BPC-157 works in people is unknown. FDA said in July 2026 that its molecular targets have not been identified, its mechanisms 'remain poorly understood', and dose-response relationships for the reported protective effects were not established. The reported effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies, not human trials [1].

Where BPC-157 sits on FDA's compounding lists

FDA keeps a list of nominated bulk drug substances for state-licensed pharmacies and physicians, and a separate list for outsourcing facilities, the larger registered compounders. BPC-157 appears on neither.

The safety-risk history is the part most often misreported. FDA placed BPC-157 in category 2 — bulk substances that may present significant safety risks when compounded — in September 2023, and it stayed there until April 22, 2026 [5][4]. On the category 2 page dated April 22, 2026 it now sits in a separate 'nominated but withdrawn' table, and the stated reason is that the groups that nominated it for the pharmacy compounding list withdrew their nominations [5][4]. Removal from that table was not a finding of safety, and the page still carries FDA's concerns [5].

Those concerns, in FDA's words: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient; FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' and 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [5].

Category 1 is the group of bulk substances FDA says it generally will not act against compounders for, if conditions are met. On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, BPC-157 is in none of the three categories, so the category 1 policy does not cover it [2]. It is also absent from FDA's list for outsourcing facilities, updated March 21, 2025 [6].

Why FDA's own reviewers recommended against listing it

In their July 2026 briefing for the advisory committee, FDA reviewers proposed that BPC-157 not be added to the pharmacy compounding list [1]. Their reasons: it is not well characterized chemically; there is little information on its safety and immunogenicity; there is insufficient evidence that it works for ulcerative colitis, the use FDA evaluated; and several FDA-approved drugs already treat ulcerative colitis [1].

The July 2026 advisory committee vote

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy compounding list, against FDA staff's recommendation [7][4]. A recommendation from an FDA advisory committee is non-binding advice [7]. BPC-157 is not on the list, and adding a bulk substance requires formal rulemaking — a proposed rule, public comment and a final rule [4].

The October 2026 HHS draft policy, in plain terms

On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy for compounding with six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. It was scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [3][4].

The operative sentence is that HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, a federal facility or a licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3][4]. For BPC-157, the draft policy covers acetate, not the free base [4]. The remaining draft conditions are:

• subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous routes are not listed [4]
• a single active ingredient [4]
• bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard [4]
• a label reading 'This is a compounded drug product. Not for resale.' [4]
• a patient-specific prescription [4]
• serious adverse events and quality problems reported to FDA MedWatch [4]
• only an FDA 510(k)-cleared syringe as a co-packaged device [4]
• documentation of adequate bioavailability for oral forms [4]

What the policy is not: it is not an FDA approval, and it does not put BPC-157 on any list [3][4]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS says it may revisit the policy, for example if a safety signal or product quality issue appears [3]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [3][4].

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [6].

How strong is the human evidence?

The human record FDA reviewed is small. FDA identified five small human studies, including conference abstracts, a retrospective chart review, a single-arm pilot in 12 women, and a two-person pilot [1]. A 2026 systematic review searched to June 1, 2026 for human studies of BPC-157 in orthopaedic and regenerative use and found three studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded it should not be used clinically outside ethically approved, regulated, high-quality trials [9].

The individual studies are small. Lee and Padgett (2021) reviewed charts at one Florida clinic: 17 patients had intra-articular knee injections, 16 were reached by phone, and 11 of the 12 who received BPC-157 alone reported significant improvement — with no control group, no validated outcome tools and recalled results [10]. Lee, Walker and Ayadi (2024) injected a total of 10 mg around the bladder wall in 12 women with interstitial cystitis who had not responded to pentosan polysulfate; 10 of 12 reported complete symptom resolution and 2 reported about 80%, in a single-arm, patient-rated pilot [11]. Lee and Burgess (2025) gave 2 adults 10 mg intravenously on day one and 20 mg on day two, with no measurable change in the heart, liver, kidney, thyroid or glucose markers tested and no reported side effects; with two participants it cannot establish safety [12].

For ulcerative colitis, FDA reviewed a 2005 conference abstract of a randomized trial: 53 people with mild to moderate disease received BPC-157 enema 80 mg or placebo daily for two weeks, and the abstract reports it was well tolerated with no difference in adverse events versus placebo [1]. FDA said the abstract has too little detail to judge effectiveness, and no full paper exists [1].

What the safety record actually contains

FDA searched its adverse-event database through December 4, 2025 and found three reports, all for injectable BPC-157: injection-site redness and swelling lasting nine days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused these [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information; in the healthy-volunteer enema studies the most frequent events were headache and flatulence [1]. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1].

Animal signals FDA noted: in 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels. Longer studies and cancer-risk studies were not available [1].

Doses that appear in the human reports

There is no FDA-approved dose, because there is no approved product [1]. The doses in the small human reports are: rectal enema up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice for knee pain; 10 mg injected into the bladder wall once for interstitial cystitis; and 10 mg then 20 mg intravenously on two days in 2 healthy adults [1]. None of these is a recommended dose [1]. FDA also found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use; after rectal enemas in two early studies, BPC-157 was mostly not detectable in blood [1].

Athletes: WADA names BPC-157

WADA's Prohibited List names BPC-157 in class S0 (non-approved substances), which covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. It is prohibited at all times, in and out of competition, and the 2026 List has been in force since January 1, 2026 [8]. WADA first named BPC-157 as an example under S0 in the 2022 List after a re-evaluation, and it stays named in the 2027 List, approved September 10, 2026 and in force January 1, 2027 [13][14].